Pipeline
We are developing therapies to counteract the devastating progression of neurodegenerative diseases.
ABC = Alector Brain Carrier
Ab = Antibody
Aβ = Amyloid Beta
AD = Alzheimer’s Disease
α-Syn = Alpha-Synuclein
ERT = Enzyme Replacement Therapy
FTD = Frontotemporal Dementia
GD = Gaucher Disease
LBD = Lewy Body Dementia
NLRP3 = NOD-, LRR-, and pyrin domain-containing protein 3
PD = Parkinson’s Disease
siRNA = Small Interference RNA
UD = Undisclosed
Close
AL101
Target
PGRN-Ab
Indication
AD
Development Stage
Phase 2
AL101 is designed to increase progranulin levels for the treatment of more prevalent neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease. Mutations that moderately reduce the expression levels of PGRN have been shown to increase the risk of developing Alzheimer’s disease and Parkinson’s disease, and increased PGRN levels have been demonstrated to be protective for these diseases in animal models.
AL101 is currently being studied in a Phase 2 clinical trial designed to assess its safety and efficacy in slowing disease progression in individuals with early Alzheimer’s disease. AL101 is being developed in collaboration with GSK.
Close
AL137-ABC
Target
Aβ-Abs
Indication
AD
Development Stage
Preclinical
AL137 is a proprietary anti-amyloid beta (Aβ) antibody paired with the company’s ABC for the treatment of AD. It is designed to remove brain amyloid plaques, with the potential to reduce the risk of amyloid-related imaging abnormalities (ARIA) and enable subcutaneous delivery. It targets a validated epitope specific to brain amyloid plaques, combined with an optimized antibody constant region to enhance phagocytosis of Aβ plaques. By leveraging ABC technology, AL137 aims to clear Aβ efficiently, thereby reducing plaque accumulation and slowing disease progression while minimizing ARIA.
Close
AL050-ABC
Target
GCase-ERT
Indication
PD, GD, LBD
Development Stage
Preclinical
AL050 is a GCase replacement therapy paired with the company’s proprietary ABC for GBA gene mutation carriers with Parkinson’s disease and Lewy body dementia. In these patients, mutations in the GBA gene lead to deficient GCase activity. AL050 uses Alector-engineered GCase, which has been designed to have a longer half-life and to break down glucocerebroside, a lipid that accumulates in neurons and contributes to neurodegeneration. This mechanism aims to reduce cellular dysfunction and slow disease progression.
Close
ADP064-ABC
Target
Tau-siRNA
Indication
AD, FTD
Development Stage
Research
ADP064-ABC targets tau pathology in Alzheimer’s disease and frontotemporal dementia. It combines an anti-tau siRNA, which inhibits the synthesis of tau mRNA and protein, with the Alector Brain Carrier to potentially slow disease progression.
Close
ADP062-ABC
Target
α-Syn-siRNA
Indication
PD
Development Stage
ADP062-ABC targets α-synuclein pathology in Parkinson’s disease. It combines an anti-α-synuclein siRNA, which inhibits the synthesis of α-synuclein mRNA and protein, with the Alector Brain Carrier to potentially slow disease progression.
Close
ADP065-ABC
Target
NLRP3-siRNA
Indication
AD, PD
Development Stage
ADP065-ABC targets NLRP3-driven neuroinflammation in Alzheimer’s disease and Parkinson’s disease. It combines an anti-NLRP3 siRNA, which inhibits the synthesis of NLRP3 mRNA and protein, with the Alector Brain Carrier to potentially slow disease progression.